跳至主要内容
临床试验/NCT01367054
NCT01367054Unknown不适用

Adverse Events in Pharmaceutical Bioequivalence Study of Two Formulations of Metformine Hydrochloride 500 mg

Biocinese1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2008年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
26
试验地点
1
主要终点
Number of Participants with Adverse Events

研究概览

简要总结

The objective is evaluate, in healthy volunteers, the bioavailability of two products containing metformine 500 mg to determine if they are bioequivalent and identify the occurrence of adverse events.

详细描述

OBJECTIVE

To evaluate, in healthy volunteers, the bioavailability of two products containing metformine 500 mg to determine if they are bioequivalent and identify the occurrence of adverse events.

MATERIAL AND METHODS

The study was approved by research Ethics Committee and all twenty-eight volunteers signed the selected IC. An open, randomized, crossover study with two periods of confinement and an interval of seven days between them was performed. Twenty (20) blood collections were performed between 30 minutes and 36 hours after drug administration. Plasma samples were analyzed by liquid chromatography mass spectrometry (LC-MS/MS). Statistical analysis was conducted based on pharmacokinetic parameters: maximum concentration (Cmax) and area under the curve (AUC 0-te AUC 0-inf). Analysis of variance (ANOVA) model appropriate was employed for the two periods cross under the logarithmically transformed data.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Within 10% of their ideal body weight
  • Age between 18 and 50 years
  • Healthy conditions
  • Ability to understand the written informed consent

排除标准

  • Pregnancy
  • Alcohol and drugs

研究组 & 干预措施

Metformin

Experimental

500 mg

干预措施: Metformin (Drug)

Metformin

Experimental

500 mg

干预措施: Glifage (Drug)

结局指标

主要结局

Number of Participants with Adverse Events

时间窗: Participants will be followed for the duration of hospital stay, an expected average of 24 hours. All adverse events observed are analyzed.

Observation of adverse events after a single dose. After administration, the volunteers need to answer the question: how are you? All complains are registered. The adverse events are going to be classified as linked ou not with the drug. The expected result is "x" volunteers presented adverse events, the most frequent was "y" event, and so one.

次要结局

未报告次要终点

研究者

发起方
Biocinese
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

Adverse Events in Pharmaceutical Bioequivalence... | 临床试验